Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple calcium injection prevent dangerous bleeding after childbirth?

NCT ID NCT07714902

Disease control Sponsor: Rambam Health Care Campus Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This trial investigates whether giving calcium gluconate right after umbilical cord clamping can reduce blood loss during vaginal delivery. Postpartum hemorrhage is a leading cause of maternal complications, and calcium is known to help with uterine contractions and clotting. About 710 women planning a vaginal delivery at 37 weeks or later will receive either calcium gluconate or a placebo, and their hemoglobin levels will be compared to see if the treatment lowers the risk of significant bleeding.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
calcium gluconate given intravenously after umbilical cord clamping
What this could lead to
If effective, this simple, low-cost intervention could become a standard way to reduce dangerous bleeding after childbirth.
What could go wrong
This is a single-center trial, and previous evidence is limited. The benefit may be small or absent, and calcium can cause side effects like nausea or vein irritation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 710 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Gestational age of 37 weeks or more, and planning a vaginal delivery. Exclusion Criteria: * Age younger than 18 years old. * Patients treated with calcium channel blockers * Patients with Preeclampsia with severe features receiving magnesium sulfate infusion. * Chronic renal failure and hyperphosphatemia * Patients with known Para-Thyroid disease * Sarcoidosis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Postpartum hemorrhage are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Postpartum Hemorrhage Uterine Inertia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Postpartum hemorrhage

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Rambam Medical Center

    RECRUITING

    Haifa, 6815408, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.